# BLISS GVS PHARMA LTD.

November 04, 2026

| | |
|---|---|
| To<br>The Manager, Listing Department<br>**National Stock Exchange of India Limited**<br>Plot no. C/1 G Block,<br>Bandra-Kurla Complex, Bandra (East),<br>Mumbai- 400 051<br>Symbol: **BLISSGVS** | To<br>The General Manager, Listing Department<br>**BSE Limited**<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai- 400 001<br>Scrip Code: **506197** |

**Subject: Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Grant of Marketing Authorisation from MHRA, UK for Mesalazine 1g Suppositories**

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), this is to inform you that Asterisk Lifesciences Ltd, UK a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products Regulatory Agency (MHRA) for Mesalazine 1g Suppositories.

Kindly take the above intimation on record.

Yours faithfully,
For **Bliss GVS Pharma Limited**

ADITI HIMANSHU BHATT

Digitally signed by ADITI HIMANSHU BHATT
Date: 2026.11.04 16:39:35 +05'30'

**Aditi H. Bhatt**
**Company Secretary & Compliance Officer**